戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 N' state, after injections of apomorphine, a dopamine receptor agonist.
2 horylated in response to direct and indirect dopamine receptor agonists.
3 oral and neural effects can be blocked by D2 dopamine receptor agonists.
4 kedly affected by systemic administration of dopamine-receptor agonists.
5 sphorylation of ERK1/2/MAP kinase, blocks D1 dopamine receptor agonist activation of ERK1/2/MAP kinas
6  In addition, we show that both the indirect dopamine receptor agonist amphetamine and the direct ago
7 triatonigral neurons induced by the indirect dopamine receptor agonist, amphetamine (AMPH).
8                                              Dopamine receptor agonist and NMDA receptor antagonist a
9 g to hD4 HEK cells was evaluated using known dopamine receptor agonists and antagonists.
10 organisms and is compatible with a number of dopamine receptor agonists and antagonists.
11 ld be to initiate therapy with a long-acting dopamine-receptor agonist and supplement at the appropri
12 gands, including pentazocine, apomorphine (a dopamine receptor agonist) and haloperidol (a dopamine r
13 hallenged with l-dopa (levodopa) and various dopamine receptor agonists, and resulting rotational beh
14       Systemic administration of the general dopamine receptor agonist apomorphine or a cocktail of t
15 and can be relieved by administration of the dopamine receptor agonist apomorphine.
16 ctivity in postnatal rats to cocaine and the dopamine receptor agonist apomorphine.
17 tions and were decreased by the nonselective dopamine receptor agonists apomorphine and L-3, 4-dihydr
18                        Administration of the dopamine receptor agonist, apomorphine (5 mg/kg, bid), a
19 ther priming with these relatively selective dopamine receptor agonists, as well as the mixed D1/D2 a
20 er dopaminergic modulation with a placebo, a dopamine receptor agonist bromocriptine or a dopamine re
21 ptoms are typically treated with levodopa or dopamine receptor agonists, but its action lacks specifi
22 e-blinded, placebo-controlled study with the dopamine receptor agonists cabergoline (a D2 agonist) an
23 ectroretinogram b-wave from cones, whereas a dopamine receptor agonist can potentiate the cone-driven
24      In contrast, 10 microM quinpirole, a D2 dopamine receptor agonist, did not activate p38 MAPK or
25                                      Because dopamine receptor agonists differentially modulate these
26                As in mammals, application of dopamine receptor agonists differentially modulates the
27                                          The dopamine receptor agonist dihydrexidine, which raised cA
28                             Priming with the dopamine receptor agonists each resulted in an enhanced
29  in direct pathway neurons in response to D1 dopamine receptor agonists either alone or when combined
30                  Apomorphine, a nonselective dopamine receptor agonist, facilitates penile erection a
31       Novel therapies include the peripheral dopamine-receptor agonist, fenoldapam, and may include e
32 e aims to present ARPE in a patient using D2 dopamine receptor agonists for the treatment of hyperpro
33 vely induced by D2-like, and not by D1-like, dopamine receptor agonists in rats.
34 als by administration of selective D(2)-like dopamine receptor agonists in the nucleus accumbens (NAc
35 yskinesias under parkinsonian conditions and dopamine-receptor-agonist induced stereotypies under nor
36             Furthermore, RGSZ1 attenuated D2 dopamine receptor agonist-induced serum response element
37             D2[1-4,7] and D2[1-5,7] mediated dopamine receptor agonist-induced stimulation and inhibi
38                        Quinpirole, a D2-like dopamine receptor agonist, induces reflexive locomotion
39  cocaine are similarly mediated, we perfused dopamine receptor agonists into the core or the shell du
40  administration of SKF 81297, a selective D1 dopamine receptor agonist known to elevate the extracell
41  examined the effects of selective D1 and D2 dopamine receptor agonists on habenular Fos expression.
42 mine receptor antagonist) and quinpirole (D2 dopamine receptor agonist) on PCP (80 mg/kg, s.c.)-induc
43  the effects of low-dose bromocriptine, a D2 dopamine receptor agonist, on processes thought to be su
44           Direct application of dopamine and dopamine receptor agonists onto trigeminocervical comple
45 mine-intact striatum, treatment with full D1 dopamine receptor agonists or stimulation of nigrostriat
46                                     The D(4) dopamine receptor agonist PD168077 induced time- and dos
47 synthetic ganglioside derivative LIGA20, the dopamine receptor agonist pramipexole (PPX) and the casp
48 3A4 substrates is bromoergocryptine (BEC), a dopamine receptor agonist prescribed for the inhibition
49                                The D1 and D2 dopamine receptor agonist properties of 7-hydroxy-2-(N,N
50  the outward IPSC by 43 %, while the D2-like dopamine receptor agonist quinpirole (10 microM) was wit
51                      Dopamine, the D(2)-like dopamine receptor agonist quinpirole and external media
52  Several studies have shown that the D2-like dopamine receptor agonist quinpirole is able to markedly
53 l administration of the D2-like (D2, D3, D4) dopamine receptor agonist quinpirole, a response that wa
54 ioural responses after challenge with the D2-dopamine receptor agonist quinpirole.
55 eurons in DD mice were hypersensitive to the dopamine receptor agonists quinpirole and SKF 81297.
56  can be reversed by the introduction of a D2 dopamine receptor agonist (Quinpirole), suggesting that
57               Treatment with D2 (but not D1) dopamine receptor agonists recovers REM sleep in these m
58                      It is hypothesized that dopamine receptor agonists reduce neuronal output from t
59 sor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonists reduced the number of histami
60                                  The D1-like dopamine receptor agonist SKF 38393 (10 microM) depresse
61 ocampal pyramidal cells revealed that the D1 dopamine receptor agonist SKF 81297 reduces peak Na(+) c
62 xaggerated in DRD mice in response to the D1-dopamine receptor agonist SKF 81297.
63                         We found that the D1 dopamine receptor agonist SKF38393 induced similar time-
64  The effects of perfusion with two selective dopamine receptor agonists SKF38393 and pergolide into t
65 drenoreceptor antagonist, timolol, the D1/D5 dopamine receptor agonist, SKF38393, and the H2 histamin
66  applied psychomotor stimulants and a direct dopamine receptor agonist to induce different levels of
67             Administration of D1- or D2-like dopamine receptor agonists to enhance dopamine signallin
68              The rank order of potencies for dopamine receptor agonists was dopamine > quinpirole > 6
69 the structure-activity relationships of D(1) dopamine receptor agonists, we investigated the roles of
70 ceptive neurons, the effects of dopamine and dopamine receptor agonists were tested on the capsaicin-
71 jor health problems in diabetic patients, D1 dopamine receptor agonists, which are already in clinica
72 rons display a supersensitive response to D1 dopamine receptor agonists, which is demonstrated by the
73 e effect of acutely delivered apomorphine, a dopamine receptor agonist with both D1 and D2 properties